An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
Start Date
6/30/2022
Completion Date
6/30/2032
Summary
To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®.
Detailed Description
This study is being conducted to obtain short-term and long-term clinical safety information from adult and pediatric patients treated for hyperammonemia due to Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA). This is an observational/non-interventional study. Patients will be treated per the prescribing information and routine medical practice. Only available data will be collected as part of the study including developmental outcomes, details of treatment with Carbaglu® and other treatments for hyperammonemia including dietary and protein management, plasma ammonia levels, pregnancy and maternal complications, adverse effects on the developing fetus and neonate, adverse effects on the infant through first year of life.
Eligibility Criteria
Age Range: No minimum to No maximum
Interventions
Carglumic Acid
Conditions
Locations
Children's National Hospital
Washington D.C., District of Columbia 20010
United States
University of South Florida
Tampa, Florida 33606
United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois 60611
United States
Riley Children's Hospital
Indianapolis, Indiana 46202
United States
Icahn School of Medicine at Mt. Sinai
New York, New York 10029
United States